European equities closed lower on Tuesday as investors remained cautious over the timing of the Fed's reduction of its stimulus program.» Read More
A look at how Roche has recently received a boost from regulators for its key medications, with Hal Barron, Roche chief medical officer.
These more targeted, or niche, drugs might only treats thousands, but they could yield higher success rates for patients and lower marketing costs for the industry.
Roche's cancer drug Avastin remains a growth driver for the company despite disappointing sales in the US and Europe as a result of regulatory restrictions, Chief Executive Severin Schwan told CNBC on Thursday.
With the markets on a decline, investors need to put money into value plays, said Rob Hoxton, president and CEO of Hoxton Financial, and Robert Auer, portfolio manager at Auer Growth Fund.
Markets are probably due for a pullback in the near-term, but for the first half of 2011, stock are going to move higher, said Andrew Kanaly, chairman of Kanaly Trust Company.
European shares are expected to open flat Friday, though concerns about the euro zone debt crisis linger and could weigh on markets.
The Food and Drug Administration rejected another new diet pill on Thursday, the latest setback in the quest to develop treatments for overweight Americans amid the nation’s obesity epidemic.
A handful of biopharma stocks could be pretty volatile this week and we're talking right up until Friday.
Deal making is officially back on with three major takeovers announced Monday. Where is the Fast Money finding alpha amid increasing acquisitions?
Results of a new study could change the way elderly patients with vision trouble are treated and have financial implications for Swiss drug giants Novartis and Roche.
Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.
It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange" at four o'clock in the morning. It was about the time that I woke up to go to work today at 1 a.m. ET that Roche and Genentech sent out their press releases announcing that their cancer drug Avastin didn't meet the main goal of a study to see if it extended the lives of people with early stage colon cancer.
M&A expert Howard Lanser reveals the next sector where he expects to see a big uptick in takeovers!
Even in this anemic market, it appears the urge to merge is alive and well.
The Dow fell modestly in choppy trade after comments from billionaire investor Warren Buffett dragged down sentiment on Monday.
Could Merck’s acquisition of Schering-Plough trigger a slew of M&A deals?
A rally in the last hour of trading lifted the Dow into positive territory on Friday, as surging oil prices drove energy stocks...
About to make a move? First, find out where Karen Finerman says there’s too much risk and too little reward to get involved.
In this Web Extra the traders game the Genentech takeover. Will Roche pull it off?
The Dow closed lower on Wednesday after President Obama warned of stricter oversight for Wall Street, raising the specter of greater regulation that investors fear could sap profits.